Evidence map›Paper›PMID 22973227›Full record

ArticleFrontiers in pharmacology2012

Development of CFTR Structure.

Anna E Patrick, Philip J Thomas

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna E PatrickDepartment of Physiology, University of Texas Southwestern Medical Center Dallas, TX, USA.
Philip J Thomas

Funding

MOLECULAR MECHANISMS OF ION TRANSPORT BY THE SMGR01DE012309 · NIDCR · UT SOUTHWESTERN MEDICAL CENTER · PI THOMAS, PHILIP J · 1997 to 2011
$4.4M
DEVELOPMENT OF MEMBRANE PROTEIN STRUCTURER37DK049835 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI THOMAS, PHILIP J · 2008 to 2017
$3.6M
Development of Membrane Protein StructureR01DK049835 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI THOMAS, PHILIP J · 1996 to 2007
$2.1M
The (Mis)Folding Pathway of CFTR: Early Interdomain and Protein InteractionsF30DK087186 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PATRICK, ANNA ELIZABETH · 2010 to 2012
$97k
NIDCR NIH HHS R01 DE012309NIDDK NIH HHS F30 DK087186NIDDK NIH HHS R01 DK049835NIDDK NIH HHS R37 DK049835
6 · The paper itself

Abstract

Cystic fibrosis is a lethal genetic disease caused by lack of functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins at the apical surface of secretory epithelia. CFTR is a multidomain protein, containing five domains, and its functional structure is attained in a hierarchical folding process. Most CF-causing mutations in CFTR, including the most common mutation, a deletion of phenylalanine at position 508 (ΔF508), are unable to properly fold into this functional native three dimensional structure. Currently, no high-resolution structural information about full length CFTR exists. However, insight has been gained through examining homologous ABC transporter structures, molecular modeling, and high-resolution structures of individual, isolated CFTR domains. Taken together, these studies indicate that the prevalent ΔF508 mutation disrupts two essential steps during the development of the native structure: folding of the first nucleotide binding domain (NBD1) and its later association with the fourth intracellular loop (ICL4) in the second transmembrane domain (TMD2). Therapeutics to rescue ΔF508 and other mutants in CFTR can be targeted to correct defects that occur during the complex folding process. This article reviews the structural relationships between CFTR and ABC transporters and current knowledge about how CFTR attains its structure-with a focus on how this process is altered by CF-causing mutations in a manner targetable by therapeutics.

Indexed as

ABC transporterCFTRcystic fibrosismembrane protein structuremultidomain protein folding

Identifiers

PMID22973227
PMCPMC3434365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.